DART: Preparing for First in Human Trials – A Thoughtful Intervention

S Dravida PhD & V Dasari PhD

Translational science stands as a pivotal mission of the 21st century, aiming to bridge the gap between scientific breakthroughs and new therapeutic innovations. The "bench-to-bedside" initiative has ignited interest in potential medical advancements, yet it carries inherent risks, particularly in the realm of human testing.

The transition from animal studies to human trials is at the heart of this process, specifically through "first-in-human" (FIH) trials. While these trials are essential for assessing new therapies, they are fraught with uncertainties and significant dangers. For instance, the TGN1412 trial and the infamous Fialuridine case illustrate the risks involved. In a 2006 Phase I study involving a CD28 superagonist antibody, six volunteers suffered life-threatening conditions after being administered a dose that was astonishingly 500 times lower than what animal testing had suggested was safe. This shocking discrepancy illustrates how flawed predictions about safety can lead to devastating outcomes in humans. Similarly, the Fialuridine trial ended tragically, with five subjects losing their lives during Phase II testing, underscoring the potential for catastrophic harm.

The inherent uncertainties present in FIH studies make it crucial to implement specialized support and mediation to guide through the process.

Phase I trials, generally involving 20 to 80 subjects, primarily focus on safety and understanding the mechanisms of action of new drugs. In 2005, the FDA introduced "exploratory IND studies," allowing for the enrollment of up to 10 participants to prioritize the collection of baseline data. To address mounting concerns about the safety of new treatments, the European Medicines Agency (EMEA) issued guidelines in 2007 for "potentially high-risk products," in response to serious adverse events. These guidelines sought to tackle pressing issues related to the mode of action of drugs and the relevance of animal models in predicting human responses.

Every FIH trial undergoes meticulous evaluation regarding preclinical evidence, trial design, and participant selection to protect human subjects while promoting scientific progress. Ethical principles mandate that risks must be minimized and justified by potential benefits. According to the Nuremberg Code, no experiment should proceed if it poses serious risks to participants, emphasizing the grave responsibility researchers carry.

Typically, FIH research involves healthy volunteers, seriously ill patients who cannot benefit from standard therapies, and those with stable diseases. The selection of the participant population is critical; healthy individuals might provide clearer data, while sick patients could yield insights more relevant to specific interventions. However, the reliance on human participants inherently introduces the risk of serious harm.

Preclinical studies can fail catastrophically due to inaccurate predictions of human response or overestimation of benefits. For instance, severe and unexpected reactions have been documented in humans at doses that were considered safe in animal studies, highlighting a distressing truth about the limitations of animal models. In some cases, artificial sweeteners are found to cause cancer in rats but have no effect on humans, further illustrating the peril of relying on animal data without thorough human evaluation.

The potential for serious harm in FIH trials cannot be overstated. The path from laboratory discovery to clinical application is fraught with dangers that can leave lasting impacts not only on the individuals involved but also on the future of medical research. Ensuring that ethical standards and participant protection are prioritized is paramount to advancing the field without sacrificing human safety.

Critics argue that enhancing preclinical processes could improve FIH trial safety

DART (Digital Animal Replacement Technology), built on an Animal-free testing strategy, can be one of the best interventions to explore for obtaining clinical surrogate readouts resembling human responses and reliable preclinical data just before FIH trials. DART studies align with anticipated human dosages and include in vitro/ex vivo testing methods in combination with AI-enabled in silico platform technology for analyzing data, supplementing scenarios and improving insights into human responses.



In the realm of medical research, the journey from the laboratory bench to the patient's bedside is fraught with challenges. The promise of innovative therapeutics often runs headlong into the daunting realities of FIH trials, where the stakes are extraordinarily high. This is where DART emerges as a groundbreaking approach, poised to transform the landscape of clinical research. Imagine a world where

every new drug could be tested with a higher degree of confidence before it ever reaches human subjects. DART is not just a method; it is a strategic paradigm shift. By utilizing advanced in vitro and ex vivo testing combined with cutting-edge AI, DART allows researchers to model human responses more accurately than ever before. This innovative platform analyzes how various dosages affect biological systems, providing essential insights that traditional methods might overlook.

The need for DART stems from a sobering reality: many drugs that appear promising in animal studies ultimately fail or cause serious adverse effects in human trials. DART aims to bridge this gap, addressing the discrepancies between animal models and human responses. By integrating physiological and pharmacological data, DART simulates human-like environments, allowing researchers to observe how potential therapeutics behave at various dosages. This process not only helps identify the most effective dose but also uncovers potential safety issues before entering FIH trials.

Picture a scenario where a new cancer treatment is being developed. With DART, researchers could simulate human responses to the drug, adjusting concentrations and observing outcomes in a controlled setting. This dynamic, real-time analysis provides crucial feedback, enabling scientists to refine their approach based on empirical evidence. As a result, when the time comes to test the treatment in humans, the team enters the trial armed with a wealth of data that informs their choices, ultimately enhancing participant safety and trial design.

Moreover, DART's ethos aligns with the ethical principles of medical research. With a focus on minimizing risks, DART ensures that every FIH trial is grounded in robust, reliable data. This level of preparedness not only protects human subjects but also fosters greater trust in the research process, allowing participants to feel confident that their involvement is contributing to advancements in medicine, not merely an experiment.

As the medical community continues to grapple with the complexities of translational science, DART stands out as a beacon of promise. By reimagining how we approach the preliminary testing phase, we can transform the trajectory of drug development. The pursuit of human health is no longer just about pushing scientific boundaries; it’s about doing so responsibly and ethically, ensuring that every step forward is a step in the right direction.

In conclusion, as we stand on the cusp of what could be a new era in drug development, embracing DART as a standard practice before FIH trials could be the key to unlocking medical breakthroughs that are not only effective but also safe.

In this journey, DART is not merely a tool; it's a commitment to advancing medicine while safeguarding those who dare to lead the way into uncharted territories of human health.